Literature DB >> 24504025

Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.

V Panagiota1, F Thol1, B Markus2, B Fehse3, H Alchalby3, A Badbaran3, U Lehmann4, C Koenecke1, R Shahswar1, A Chaturvedi1, M Stadler1, M Eder1, G Göhring5, M Koenigsmann6, A Kloos1, A Trummer1, T Schroeder7, G Kobbe7, C Thiede8, U Platzbecker8, B Schlegelberger5, H-H Kreipe4, A Ganser1, N Kröger3, M Heuser1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24504025     DOI： 10.1038/leu.2014.66

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.

Authors:  Haefaa Alchalby; Dinah-Rohina Yunus; Tatjana Zabelina; Guido Kobbe; Ernst Holler; Martin Bornhäuser; Rainer Schwerdtfeger; Wolfgang Bethge; Hans Michael Kvasnicka; Guntram Büsche; Francis Ayuk; Ulrike Bacher; Axel R Zander; Nicolaus Kröger
Journal:  Br J Haematol       Date:  2012-01-27       Impact factor: 6.998

2.  Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.

Authors:  Haefaa Alchalby; Anita Badbaran; Tatjana Zabelina; Guido Kobbe; Joachim Hahn; Daniel Wolff; Martin Bornhäuser; Christian Thiede; Herrad Baurmann; Wolfgang Bethge; York Hildebrandt; Ulrike Bacher; Boris Fehse; Axel R Zander; Nicolaus Kröger
Journal:  Blood       Date:  2010-05-20       Impact factor: 22.113

3.  Calreticulin exposure dictates the immunogenicity of cancer cell death.

Authors:  Michel Obeid; Antoine Tesniere; François Ghiringhelli; Gian Maria Fimia; Lionel Apetoh; Jean-Luc Perfettini; Maria Castedo; Grégoire Mignot; Theoharis Panaretakis; Noelia Casares; Didier Métivier; Nathanael Larochette; Peter van Endert; Fabiola Ciccosanti; Mauro Piacentini; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

4.  Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte.

Authors:  Shyra J Gardai; Kathleen A McPhillips; S Courtney Frasch; William J Janssen; Anna Starefeldt; Joanne E Murphy-Ullrich; Donna L Bratton; Per-Arne Oldenborg; Marek Michalak; Peter M Henson
Journal:  Cell       Date:  2005-10-21       Impact factor: 41.582

5.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

6.  International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

Authors:  Kebede Hussein; Animesh D Pardanani; Daniel L Van Dyke; Curtis A Hanson; Ayalew Tefferi
Journal:  Blood       Date:  2009-11-09       Impact factor: 22.113

7.  Witch hunt against tumor cells enhanced by dendritic cells.

Authors:  Clara Locher; Sylvie Rusakiewicz; Antoine Tesnière; François Ghiringhelli; Lionel Apetoh; Guido Kroemer; Laurence Zitvogel
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

8.  Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Nicolaus Kröger; Ernst Holler; Guido Kobbe; Martin Bornhäuser; Rainer Schwerdtfeger; Herrad Baurmann; Arnon Nagler; Wolfgang Bethge; Matthias Stelljes; Lutz Uharek; Hannes Wandt; Andreas Burchert; Paolo Corradini; Jörg Schubert; Martin Kaufmann; Peter Dreger; Gerald G Wulf; Hermann Einsele; Tatjana Zabelina; Hans Michael Kvasnicka; Jürgen Thiele; Ronald Brand; Axel R Zander; Dietger Niederwieser; Theo M de Witte
Journal:  Blood       Date:  2009-10-07       Impact factor: 22.113

9.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

10.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245
View more
  25 in total

Review 1.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

2.  Somatically acquired mutations in primary myelofibrosis: A case report and meta-analysis.

Authors:  Yongming Xia; Qingxiao Hong; Zhibin Gao; Shijun Wang; Shiwei Duan
Journal:  Exp Ther Med       Date:  2021-01-07       Impact factor: 2.447

Review 3.  Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Authors:  Rachel B Salit; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2014-10-03       Impact factor: 3.722

4.  Low frequency of calreticulin mutations in MDS patients.

Authors:  M Heuser; V Panagiota; C Koenecke; B Fehse; H Alchalby; A Badbaran; R Shahswar; M Stadler; M Eder; G Göhring; A Trummer; T Schroeder; G Kobbe; C Thiede; U Platzbecker; B Schlegelberger; N Kroeger; A Ganser; F Thol
Journal:  Leukemia       Date:  2014-05-21       Impact factor: 11.528

5.  Mutant calreticulin in myeloproliferative neoplasms.

Authors:  Joan How; Gabriela S Hobbs; Ann Mullally
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

6.  Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis.

Authors:  M Christopeit; A Badbaran; T Zabelina; G Zeck; B Fehse; F Ayuk; C Wolschke; N Kröger
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

7.  Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

Authors:  Nicolaus Kröger; Toni Giorgino; Bart L Scott; Markus Ditschkowski; Haefaa Alchalby; Francisco Cervantes; Alessandro Vannucchi; Mario Cazzola; Enrica Morra; Tatjana Zabelina; Margherita Maffioli; Arturo Pereira; Dietrich Beelen; H Joachim Deeg; Francesco Passamonti
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

Review 8.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

Review 9.  Current Challenges in Stem Cell Transplantation in Myelofibrosis.

Authors:  Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

10.  MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

Authors:  Damiano Rondelli; Judith D Goldberg; Luis Isola; Leah S Price; Tsiporah B Shore; Michael Boyer; Andrea Bacigalupo; Alessandro Rambaldi; Marco Scarano; Rebecca B Klisovic; Vikas Gupta; Bjorn Andreasson; John Mascarenhas; Meir Wetzler; Alessandro M Vannucchi; Josef T Prchal; Vesna Najfeld; Attilio Orazi; Rona S Weinberg; Crystal Miller; Giovanni Barosi; Lewis R Silverman; Giuseppe Prosperini; Roberto Marchioli; Ronald Hoffman
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.